4//SEC Filing
Avagliano Mark 4
Accession 0001562180-23-000251
CIK 0001560241other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:25 PM ET
Size
11.7 KB
Accession
0001562180-23-000251
Insider Transaction Report
Form 4
Avagliano Mark
Chief Business Officer
Transactions
- Award
Stock Options (Right to buy)
2023-01-03+41,100→ 41,100 totalExercise: $5.73Exp: 2033-01-03→ Common Stock (41,100 underlying) - Award
Common Stock
2023-01-03+20,600→ 42,155 total
Footnotes (4)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 7,055 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 20,600 RSUs from award granted on January 3, 2023.
- [F4]The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Issuer
G1 Therapeutics, Inc.
CIK 0001560241
Entity typeother
Related Parties
1- filerCIK 0001783503
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:25 PM ET
- Size
- 11.7 KB